IRMD earnings analysis
What we found in IRMD's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Iradimed Corporation reported strong Q1 2026 results featuring revenue of $22.0 million and EPS of $0.45, both exceeding analyst expectations. Revenue grew 13% year-over-year, driven by robust sales of MRI compatible medical devices, while operating cash flow nearly doubled compared to the previous year, demonstrating solid operational performance.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth
- Q1 2026 revenue increased 13% to $22.0 million, up from $19.5 million in Q1 2025.
- EPS Beat
- Diluted EPS was reported at $0.45, surpassing estimates of $0.44.
- Improved Cash Flow
- Operating cash flow nearly doubled to $8.3 million, up 93% from $4.3 million year-over-year.
- Strong Device Sales
- Revenue from MRI compatible devices grew 19% to $15.4 million, driven by high demand.
- Reduction in Operating Expenses
- Total operating expenses as a percentage of revenue decreased to 43.6% from 48.2% year-over-year.
- Increased Gross Margin
- Gross margin improved to 77%, up from 76% in the prior year.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Pending Tariff Refunds
- Recent Supreme Court ruling on tariffs may affect cost structures; the timing and realization of refunds for incurred costs remain uncertain.
- Market Uncertainties
- Global geopolitical tensions may impact supply chains and international market conditions, introducing risk to operations.
- Regulatory Approvals
- Dependence on regulatory approvals for medical devices can pose significant risks to product availability and revenue.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.49
- Gross margin
- 77%
- Operating margin
- 32.9%
- Segment
- Devices: $15.4M
- Segment
- Amortization of extended maintenance: $0.659M
- Segment
- Disposables: $4.885M
- Segment
- Services: $1.043M
What they said about what is next.
Full-year guidance remains unchanged from prior estimates.
The filing reads better than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing IRMD makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever